Hundreds of patients to benefit from revolutionary lung cancer drug on the NHS

Hundreds of patients to benefit from revolutionary lung cancer drug on the NHS A revolutionary targeted drug for lung cancer will be made available to anyone who is eligible, thanks to a new drug deal, the head of the NHS announced today.

Sotorasib targets a genetic mutation, dubbed the ‘death star’, by medics and scientists, and has been proven during trials to prevent lung cancer from growing for seven months. NHS England